Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-23Clinical Trial Update: A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies [Phase 1]
Pfizer's Phase 1 trial of PF-08046037 alone or with sasanlimab in advanced cancers has been terminated.
-
CLINICAL_TRIALS other · 2026-04-23Clinical Trial Update: Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab [Phase 1]
A Phase 1 study evaluating a personalized neoantigen dose-adjusted vaccine in combination with pembrolizumab for squamous cell cancers of th…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: ctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC [Phase 2]
A Phase 2 clinical trial evaluating ctDNA-MRD guided consolidation therapy with toripalimab in stage IB-IIIA non-small cell lung cancer, cur…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors [Phase 1, Phase 2]
Ongoing Phase 1/2 clinical trials evaluating elironrasib and daraxonrasib as solo therapies and in combination for advanced KRAS G12C-mutant…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) [Phase 1, Phase 2]
This document reports a Phase 1/2 clinical trial evaluating the anti-CEACAM5 antibody-drug conjugate M9140 in adults with advanced solid tum…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: A Study of BMS-986504 in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9) [Phase 2]
A Phase 2 clinical trial update for BMS-986504 in pre-treated advanced or metastatic non-small cell lung cancer with homozygous MTAP deletio…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors [Phase 1, Phase 2]
A Phase 1/2 clinical trial of GTAEXS617 in adults with advanced solid tumors is currently recruiting. The study encompasses head and neck sq…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors [Phase 1, Phase 2]
AstraZeneca is conducting a Phase 1/2 trial to evaluate the safety of AZD6750 in adults with select advanced or metastatic solid tumors; the…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) [Phase 3]
A Phase 3 clinical trial (Chemo-IO ACCIO) is evaluating adding an immunotherapy agent to standard chemotherapy for non-small cell lung cance…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) [Phase 3]
This clinical trial update reports a Phase 3 study comparing Sacituzumab Tirumotecan (MK-2870) to chemotherapy in previously treated advance…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Bevacizumab Plus Nab-paclitaxel and Platinum for Immunotherapy-treated Non-squamous Non-small Cell Lung Cancer [NA]
This clinical trial update outlines a study evaluating bevacizumab in combination with nab-paclitaxel and platinum for metastatic non-squamo…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) [Phase 3]
This Phase 3 clinical trial is evaluating pembrolizumab with or without Intismeran Autogene (V940) in participants with non-small cell lung …
-
CLINICAL_TRIALS trial_result · 2026-04-23Clinical Trial Update: Stereotactic Radiosurgery in Treating Patients Undergoing Chemotherapy and Radiation Therapy For Stage III Non-Small Cell Lung Cancer [NA]
The ClinicalTrials.gov study NCT00945451 investigates the use of stereotactic radiosurgery for patients with stage III non-small cell lung c…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Vebreltinib Plus Chemotherapy as First-line Treatment for MET-overexpressing NSCLC [Phase 2]
A Phase 2 trial evaluating Vebreltinib in combination with chemotherapy as first-line treatment for MET-overexpressing non-small cell lung c…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation [Phase 3]
Phase 3 trial update evaluating durvalumab with stereotactic body radiation therapy (SBRT) versus placebo with SBRT in early-stage unresecte…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. [Phase 1]
Pfizer's PF-07799933 is being studied in a Phase 1 trial for advanced solid tumors with BRAF alterations. The study includes melanoma, non-s…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors [Phase 1]
Pfizer is conducting a Phase 1 study of PF-07799544 as a monotherapy or in combination for advanced solid tumors, including melanoma and gli…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer [Phase 3]
Phase 3 trial assessing osimertinib with or without bevacizumab as initial therapy for EGFR-mutant non-small cell lung cancer; the study is …
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection [Phase 3]
A global Phase 3 study evaluating osimertinib as adjuvant therapy in patients with EGFR-mutant stage IA2-IA3 non-small cell lung cancer afte…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection [Phase 3]
A Phase 3 trial evaluating Zipalertinib versus placebo as adjuvant therapy for Stage IB-IIIA non-small cell lung cancer with uncommon EGFR m…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC) [Phase 1]
Phase 1 study evaluating gilteritinib in adults with advanced ALK-positive non-small cell lung cancer is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Phase 1 Study of PF-08046033 in Advanced Solid Tumors [Phase 1]
Pfizer is evaluating PF-08046033 in a Phase 1 trial for adults with advanced solid tumors, including non-small cell lung cancer, esophageal …
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study [NA]
A Phase II trial is evaluating a double-dose third-generation EGFR-TKI combined with bevacizumab and intrathecal chemotherapy for leptomenin…
-
EMA approval · 2026-04-22EMA Authorised: Keytruda (pembrolizumab) — Merck Sharp & Dohme B.V.
The European Medicines Agency authorised Keytruda (pembrolizumab) for multiple cancer indications, including melanoma, Hodgkin lymphoma, ren…
-
CLINICAL_TRIALS trial_result · 2026-04-22Clinical Trial Update: Patient-Reported Outcomes Following Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer [Phase 2]
Phase 2 trial results reporting patient-reported outcomes after chemoradiotherapy for locally advanced non-small cell lung cancer.